Stay updated on Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Sign up to get notified when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.

Latest updates to the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page
- Check2 days agoChange DetectedMinor version update: Revision changed from v3.3.3 to v3.3.4, with no changes to core content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoChange DetectedLocations updated: two new sites in Tokyo (tabashi City, 173-0015 and Setagaya-Ku, 156-0057) were added and a Tampa site was withdrawn, bringing the total locations to 411.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe ADEPT-3 study added numerous new locations across the globe, including sites in China, Argentina, and the United States (e.g., 7021, 7023–7028). The total number of study locations now reaches 409.SummaryDifference3%

- Check52 days agoChange DetectedNew locations and site details were added (e.g., Site 4215 in Iława, Poland and Site 1246 in Naples, FL) and investigator contacts updated. The total number of reported locations now stands at 397.SummaryDifference0.7%

- Check60 days agoChange DetectedAdded 'Last Update Posted (Estimated)' under Study Record Dates. Removed the government funding lapse notice.SummaryDifference0.1%

- Check67 days agoChange DetectedAdded new locations and site details (including Seoul, South Korea; Greater Poland Voivodeship, Poland; São Paulo, Brazil) and removed several sites, with the total locations now listed as 393.SummaryDifference0.7%

Stay in the know with updates to Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.